(Q39544958)

12 September 2017

Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial (English)

1 reference

12 September 2017

0 references

1 reference

2

E K N'Goran

1 reference

12 September 2017

J Utzinger

1

1 reference

12 September 2017

A N'Dri

3

1 reference

12 September 2017

C Lengeler

4

1 reference

12 September 2017

S Xiao

5

1 reference

12 September 2017

M Tanner

6

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

12 September 2017

1 reference

12 September 2017

355

1 reference

12 September 2017

9212

1 reference

12 September 2017

1320-1325

1 reference

Schistosomiasis vaccine:research to development

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Schistosomiasis: forty years' war on the worm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Use of praziquantel against schistosomiasis: a review of current status.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Chemotherapy of schistosomiasis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Praziquantel--its use, cost and possible development of resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Reinfection after treatment of schistosome infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

The prophylactic effects of artemether against Schistosoma japonicum infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Protection against schistosomiasis produced by cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Qinghaosu (artemisinin): an antimalarial drug from China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Preventive effect of artemether in experimental animals infected with Schistosoma mansoni

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Schistosoma mansoni: chemotherapy of infections of different ages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Schistosoma mansoni, intestinal parasites and perceived morbidity indicators in schoolchildren in a rural endemic area of western Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Underestimation of Schistosoma mansoni prevalences.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

Averting a malaria disaster

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902114-0

7 January 2021

10.1016/S0140-6736(00)02114-0

Identifiers

DOI

1 reference

12 September 2017

1 reference